Related Experiment Video
Updated: Feb 16, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B
1Department of Pathology & Molecular Medicine, Richardson Laboratory, Queen's University, Kingston, Ontario K7L 3N6, Canada.
Abstract:
A phase 1/2 clinical trial of AAV-mediated gene therapy in patients with hemophilia B using an enhanced specific activity factor IX (FIX) transgene reports sustained levels of FIX levels, leading to the near elimination of bleeding for more than a year and without serious adverse side effects. These results are the best outcome to date for hemophilia gene therapy.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Gene Therapy
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Pharmacogenomics: Identification of New Drug Targets

